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CASE REPORT
Progressive multifocal exophytic pontine 
glioblastoma: a case report with literature 
review
Fanfan Chen1, Zongyang Li2, Chengyin Weng3, Peng Li1, Lanbo Tu1, Lei Chen2, Wei Xie1 and Ling Li4*
Abstract 
Multifocal pontine glioblastoma exhibiting an exophytic growth pattern in the cerebello-pontine angle (CPA) is rare. 
We present a case of a 5-year-old girl with consecutive neurological imaging and other clinical findings indicat-
ing progressive multifocal exophytic pontine glioblastoma. Three lesions were reported, of which two were initially 
presented, and one was developed 2 months later. One lesion demonstrated a progressing exophytic extension in the 
cistern of the left side of the CPA. The other two lesions were located and confined within the pons. Initial magnetic 
resonance imaging and positron emission tomography–computed tomography indicated low-grade glioma or 
inflammatory disease. However, 2 and 3 months later, subsequent magnetic resonance spectroscopy (MRS) displayed 
elevated choline and depressed N-acetyl aspartate peaks compared with the peaks on the initial MRS, indicating 
a high-grade glioma. Subtotal resection was performed for the CPA lesion. Histopathologic examination showed 
discrepant features of different parts of the CPA lesion. The patient received no further chemotherapy or radiotherapy 
and died 2 months after surgery. The multifocal and exophytic features of this case and the heterogeneous manifes-
tations on neurological images were rare and confusing for both diagnosis and surgical decision-making. Our case 
report may contribute knowledge and helpful guidance for other medical doctors.
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Background
Although brainstem tumors account for 10%–20% of cer-
ebral neoplasms in children and 90% of them are gliomas 
[1, 2], exophytic pontine glioma located in the cerebello-
pontine angle (CPA) is uncommon [3–6]. Because of 
their heterogeneous biological behaviors and neurologi-
cal imaging manifestations, the classification of brain-
stem gliomas is not consistent. Diagnosis and therapeutic 
decision-making are often difficult for gliomas, especially 
in the case of rare neurological imaging features.
Here, we report a special case of multifocal glioblas-
toma derived from the pons, exhibiting an exophytic 
growth pattern, in a 5-year-old girl. In total, three lesions 
were revealed in the posterior fossa. Repeated magnetic 
resonance imaging (MRI) showed the progression of the 
lesions in the left side of the CPA and the upper left side 
of the pons as well as the appearance of a new lesion in 
the right side of the pons. Furthermore, repeated mag-
netic resonance spectroscopy (MRS) over 3  months 




The 5-year-old girl was admitted to the Neurosurgery 
Department of Guangzhou First People’s Hospital, 
Guangzhou, China on October 6, 2015 and presented 
with a 2 month history of a medial gaze of the left eye. 
She did not complain of headache, dizziness, dys-
phagia, or vomiting. The outpatient medical record 
revealed that the patient frequently had fevers and 
coughs since the age of three. The last fever and cough 
were reported 1 week before the admission. The patient 
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showed age-appropriate physical development. Cardio-
pulmonary auscultation results were normal. A neuro-
logical examination revealed left cranial VI nerve palsy 
without involvement of other nerves such as the ocular 
motor (cranial III or IV), trigeminal, facial, and acous-
tic nerves. No cerebellar signs or hemiparesis were pre-
sent. The patient showed no signs of ataxia or long tract 
dysfunction.
Gadolinium-enhanced magnetic resonance imaging 
(MRI) was performed 2  days after the admission, dem-
onstrating two well-defined, ring-enhanced lesions at 
the left side of the CPA (2.0 cm × 2.6 cm; Fig. 1A) and 
upper left side of the pons (0.6  cm  ×  0.5  cm; Fig.  1B). 
The MRI manifestation of the CPA lesion was similar to 
an extra-axial mass, e.g., nerve sheath tumor. The pons 
was obviously enlarged and swollen. MRS displayed a 
simultaneous decrease in N-acetyl aspartate (NAA) and 
choline (Cho) (Fig.  1C). The Cho:NAA ratio was 0.82, 
and the Cho:Cr (creatine) ratio was 13.01. A peak at 1.3 
part per million (ppm) was observed. Positron emission 
tomography–computed tomography (PET–CT) was 
performed, which demonstrated hypometabolic foci in 
the left side of the CPA, indicating low-grade glioma or 
inflammation (Fig. 1D).
Fig. 1 Images of the initial magnetic resonance imaging (MRI) and positron emission tomography–computed tomography (PET–CT) on Oct 8, 
2015 for the 5-year-old girl with multiple posterior fossa lesions. A Axial gadolinium-enhanced MRI displays a lesion (2.0 cm × 2.6 cm; white arrow) 
in the cerebello-pontine angle (CPA). No relatively clear margin was observed between the lesion and the pons. B Sagittal gadolinium-enhanced 
MRI shows two lesions. The upper left pontine lesion (0.5 cm × 0.6 cm) was significantly gadolinium-enhanced with relatively clear margin (red 
arrow). From the sagittal view, the CPA lesion (white arrow) seemingly demonstrates clear boundary to the pons. C Magnetic resonance spectros-
copy (MRS) of the lesion shows a decrease in choline (Cho) and N-acetyl aspartate (NAA). D PET–CT image demonstrates a hypometabolic lesion 
(white arrow) in the left side of the CPA
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The patient showed weak expression of serum antibod-
ies for tubercle bacillus (TB). The results of sputum smear 
examination and blood interferon-gamma release assay 
for the detection of TB infection were negative. Serum 
levels of tumor markers [including alpha-fetoprotein, car-
cinoembryonic antigen, carbohydrate antigen (CA)-724, 
CA-125, CA-199, and squamous cell carcinoma antigen] 
were within normal ranges, except for a slight increase in 
the level of neuron-specific enolase. The cerebrospinal 
fluid was extracted via lumbar puncture and tested for 
TB-DNA and TB-RNA, yielding negative results. After 
consultation with a tuberculosis specialist, the current 
evidence for intracranial tuberculoma was deemed insuf-
ficient. We proposed a biopsy of the left CPA lesion, but 
the patient’s parents refused and demanded discharge.
Two months later, the patient underwent another 
MRI. No involvement of additional nerves was observed, 
except for the cranial VI palsy. However, progression of 
the disease was demonstrated: (1) the left CPA lesion was 
enlarged and extended along the cistern of CPA (Fig. 2A, 
B, white arrow); (2) the upper left pontine lesion was 
enlarged (Fig. 2B, red arrow); and most importantly, (3) 
a new lesion had emerged in the upper right side of the 
pons (Fig. 2A, yellow arrow). In addition, MRS revealed 
a radical decrease of NAA and a drastic increase of 
Cho with an obvious increase in the Cho:NAA ratio 
(Cho:NAA  =  1.56) and a decrease in the Cho:Cr ratio 
(Cho:Cr = 11.87) (Fig. 2C). A peak at 1.3 ppm was dis-
played. We strongly suggested surgery for pathologic 
diagnosis and follow-up treatment as soon as possible, 
but the parents refused again.
One month later, the patient was admitted again 
because of malnutrition and weakness with frequent 
vomiting. Re-examination with MRI demonstrated pro-
gression of all three lesions, especially the CPA lesion, 
which progressed and expanded to the anterior CPA cis-
tern (Fig. 2D, E). MRS data showed the same pattern as 
the previous examination, with a significantly increased 
Fig. 2 Images of repeated MRI on Dec 11, 2015 and Jan 12, 2016 for the 5-year-old girl with multiple posterior fossa lesions. A Axial gadolinium-
enhanced MRI (Dec 11, 2015) displays the occurrence of a new lesion (0.8 cm × 0.9 cm, yellow arrow). The left CPA lesion is enlarged and extended 
along the cistern of the CPA (3.1 cm × 1.2 cm, white arrow). B Sagittal gadolinium-enhanced MRI (Dec 11, 2015) shows that the CPA lesion was 
enlarged and extended along the cistern of CPA (white arrow) and the upper left pontine lesion was enlarged (red arrow). C MRS (Dec 11, 2015) 
shows increased Cho and decreased NAA expression. The Cho:NAA ratio was also significantly increased. D Axial gadolinium-enhanced MRI (Jan 12, 
2016) displays that both the CPA lesion (white arrow) and the new lesion in the right side of the pons are enlarged (1.1 cm × 1.3 cm, yellow arrow). 
The CPA lesion is extended along the cistern of the CPA. E Sagittal gadolinium-enhanced MRI (Jan 12, 2016) shows that both the CPA lesion (white 
arrow) and upper left pontine lesion (red arrow) were enlarged. F MRS (Jan 12, 2016) shows further increased Cho and decreased NAA expression. 
The Cho:NAA ratio was 2.33
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Cho:NAA ratio (Cho:NAA  =  2.33) and dramatically 
decreased Cho:Cr ratio (Cho:Cr  =  1.38) (Fig.  2F). A 
reverse peak at 1.3  ppm was shown. The parents finally 
agreed to the suggested surgery.
Surgery and pathology
Histopathologic diagnosis and safe resection of the lesion 
were the goals of the suggested surgery. Under these cir-
cumstances, the CPA lesion was the target of the opera-
tion, whereas the other two lesions were left untouched. 
The surgery was conducted using a suboccipital retrosig-
moid approach. After occipital craniotomy and dura 
opening, the cerebellum was cautiously separated from 
the CPA, and the cerebrospinal fluid was slowly released 
and suctioned. The arachnoid of the CPA was opened, 
and a yellowish nodule-like mass was encountered with 
a clear boundary to the cerebellum (Fig. 3a). The vessels 
distributed on the surface of the lesion were carefully 
coagulated, and the lesion was moderately rubbery. The 
tissue was formalin-fixed and paraffin-embedded for a 
pathologic examination with hematoxylin–eosin stain-
ing, which indicated moderate mitoses, necrosis, and 
vascularization, suggesting low-grade glioma (Fig.  3b, 
c). Resection of the lesion combined with ventricular 
peritoneal drainage was performed. The internal portion 
of the lesion, with a relatively higher blood supply, was 
softer than the outer layer (Fig.  3d). No clear boundary 
was found between the lesion and the pons or the root 
entry zone of the trigeminal nerve. Histopathologic 
examination revealed a highly malignant tumor with 
marked necrosis and vascularization (Fig.  3e, f ). No 
typical pseudopalisading signs or glomerular structures 
were observed in this case. The internal portion of the 
CPA lesion was removed within the arachnoid boundary 
until neurophysiological monitoring of the caudal cranial 
nerves displayed a slightly decreasing reaction. Postop-
erative MRI confirmed the subtotal resection of the CPA 
lesion. No further surgery-related neurological deficits 
occurred.
The final pathologic diagnosis was glioblastoma with 
diffuse and strong expression of glial fibrillary acid pro-
tein (GFAP, Fig. 4a) and S-100 (Fig. 4b). The positive rates 
were 80%–90% for both P53 (Fig. 4c) and Ki-67 (Fig. 4d) 
and 1% for methylated O6-methylguanine-DNA meth-
yltransferase (Fig. 4e). The expression of isocitrate dehy-
drogenase 1 (IDH1) was weak (Fig. 4f ).
The patient received no further chemotherapy or radio-
therapy and died 2 months later.
Discussion
The preoperative diagnosis of this case was difficult. 
Brain metastases, central nervous system (CNS) lym-
phomas, and inflammatory disease were considered in 
the differential diagnosis. It is notable that the patient 
Fig. 3 Histopathologic examination of the CPA lesion with hematoxylin–eosin staining. a Macroscopically, the outer layer of CPA lesion is rubbery 
and nodule-like. b Under a microscope, the outer layer of the CPA lesion displays moderate mitoses and necrosis. c Under a microscope, the outer 
layer of the CPA lesion displays moderate vascularization. d Macroscopically, the internal portion of the lesion is softer and has a higher blood sup-
ply than the outer layer. e Under a microscope, the internal portion of the CPA lesion displays obvious mitoses and necrosis. f Under a microscope, 
the internal portion of the CPA lesion displays hyper-vascularization
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presented with frequent fever and cough and had weak 
positivity for blood TB antibodies. Infectious diseases, 
such as tuberculosis, were considered. Although previ-
ous articles mentioned that ring-like enhancement and 
multiple lesions are indications of posterior fossa glio-
blastoma [7], these neurological imaging features are fre-
quently observed in tuberculoma and tuberculous lesions 
that are occasionally secondary to tuberculous arach-
noiditis [8]. Surgical resection or biopsy is necessary for a 
definitive diagnosis. The histological grading is based on 
the degree of anaplasia and dedifferentiation, number of 
mitoses, capillary endothelial proliferation, and presence 
of necrosis [9–11].
Immunohistochemical examination showed diffuse 
expression of GFAP, P53, and S-100 in our case. The 
expression of S-100 is not stable in glioma, whereas 
GFAP is a qualitative diagnostic marker of glioma [12]. 
The combination of all histopathologic evidence sup-
ported the diagnosis of glioblastoma in our case.
The progressive growth pattern of the CPA lesion is a 
confusing characteristic of this case, especially given the 
coexistence of multiple lesions. We searched PubMed 
and Google Scholar and found only two English-language 
articles reporting the coexistence of multiple lesions and 
a CPA lesion [13, 14]. According to the literature, CPA 
glioblastomas may have different origins [15]. Wu et  al. 
[16] reported a CPA glioblastoma that originated from 
the cranial VIII nerve and reviewed seven other similar 
cases. Cranial nerve glioblastomas are presumably origi-
nated from CNS tissue locating at the root entry zone of 
the cranial nerve or from heterotopic neuroglia cells in 
the leptomeninges. Similarly, Mabray et al. [17] recently 
reported eight cases of glioblastoma originated from the 
cranial nerve. These glioblastomas were located at the 
CPA and involved the unilateral brainstem. The cerebel-
lum is another unusual place for glioblastoma develop-
ment. Matsuda et al. [18] reported a case of glioblastoma 
originated from the cerebellum and reviewed another 
three similar cases. In the reports by both Mabray et al. 
[17] and Matsuda et al. [18], the relatively clear boundary 
between the brainstem and tumor were demonstrated 
during the operation. In our case, neither preoperative 
MRI nor surgery alone supported an origin at the cranial 
nerve cerebellum. However, no clear boundary between 
the CPA lesion and the pons was discovered during our 
surgical procedure. This evidence, along with MRI find-
ings on the CPA lesions and two pontine lesions, con-
firmed the diagnosis of primary exophytic pontine 
glioblastoma. The T2-weighted image showed that the 
CPA lesion was confined to the pons, with an outer layer 
that consisted of edematous tumor tissue infiltrating 
the pons. This finding may explain that the pathologic 
presentation of the outer layer of the tumor was not as 
typical for glioblastoma as that of the inner part of the 
tumor, emphasizing the diverse pathologic features of 
different parts of the tumor and the need for accurate and 
Fig. 4 Immunohistochemical examination of the tumor with diaminobenzidine staining. Glial fibrillary acidic protein (a), S-100 (b), P53 (c), and 
Ki-67 (d) are diffusely expressed. The expression of methylated O6-methylguanine-DNA methyltransferase (e) and isocitrate dehydrogenase 1 (f) is 
weak
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comprehensive specimen collection in such a case. As 
reported earlier, the biopsy samples should be collected 
from solid, non-necrotic, and gadolinium-enhanced 
areas, if possible [19].
According to the imaging and histopathologic evi-
dence, this case of pontine glioblastoma can be catego-
rized as a brainstem glioma. However, the classification 
of brainstem gliomas is not uniform. Choux et  al. [20] 
classified brainstem tumors as diffuse glioma, focal 
intrinsic glioma (solid or cystic), exophytic glioma, and 
cervicomedullary glioma. Fisher et  al. [21] anatomically 
classified brainstem glioma as diffuse intrinsic pontine 
glioma (DIPG), exophytic medullary glioma, and mid-
brain or tectal glioma. However, they also considered it 
was reasonable to categorize brainstem tumors simply as 
diffuse or focal glioma. Our case possessed some typical 
features of DIPG, such as an infiltrative lesion occupy-
ing 50% of the pons, obvious expansion of the pons, and 
engulfment of the basilar artery as reported in the lit-
erature [22, 23]. DIPG may extend laterally into the cer-
ebellar peduncles, cerebellar hemispheres, midbrain, and 
medulla [24], whereas the exophytic growth to the CPA 
is not a common feature of typical DIPG. This situation 
may explain why some researchers exclude exophytic 
pontine glioma from the diagnostic criteria of DIPG [22, 
25]. Given that various manifestations of DIPG are often 
observed, the term “atypical DIPG” was adopted by some 
researchers [26]. It seems that our case may be classified 
as diffuse brainstem (pontine) glioma or an atypical sub-
type of DIPG (Table 1).
The changes in the MRS results of our case merit atten-
tion. It was reported that the Cho:NAA ratio calculated 
according to MRS data can be used to monitor metabo-
lism and glioma behavior [22]. In pediatric CNS tumors, 
changes in levels of metabolic markers as determined 
with MRS are associated with tumor grade [27]. Fur-
thermore, an increasing Cho:NAA ratio predicts a short 
overall survival [22, 28]. PET measures the regional cer-
ebral glucose metabolism, offering valuable information 
that can be used to differentiate between low-grade and 
high-grade gliomas [29–31]. For our case, the initial MRS 
results (obtained on October 8, 2015) showed a simul-
taneous decrease in NAA and Cho and an increased 
Cho:NAA ratio, leading to the diagnosis of low-grade 
glioma. The decrease in NAA, Cho, and Cho:NAA ratio 
of the first MRS may be technique variations such as 
the selection bias of regions of interests. Taking both 
MRS and PET results into consideration, a diagnosis of 
low-grade glioma seems reasonable. Earlier PET find-
ings from another medical center were consistent with 
our initial MRS results. Repeated MRS performed 2 
and 3  months later demonstrated an obvious decrease 
in NAA and an increase in Cho, indicating a high-grade 
glioma. In addition, we noticed peaks at approximately 
1.3 ppm (Figs. 1c, 2c, f ). Two situations were considered: 
(1) technical problems such as unstable baseline or lipid 
effection and (2) a lac-lip peak demonstrating necrosis or 
hypoxia. Although necrosis is usually found in high-grade 
glioma, PET–CT results and the increasing tendency of 
the Cho:NAA ratio both support the initial diagnosis of 
low-grade glioma. The MRS characteristics of this tumor 
seemed to be significantly altered within merely 2 months 
according to consecutive neurological imaging.
Glioblastomas are divided into two types of genesis 
patterns: primary glioblastoma, also termed de novo glio-
blastoma, which is defined as a fully developed tumor 
with no clinical, radiological, or histopathologic evi-
dence of relative benign precursor lesion [32–34], and 
secondary glioblastoma progressing from low-grade 
astrocytoma, as supported by imaging or histological evi-
dence [32, 33, 35]. According to the literature, the pro-
portions of primary and secondary glioblastomas are 
approximately 90% and 10%, respectively [36]; the disease 
course of primary glioblastomas was less than 3 months, 
whereas the progression from relative low-grade astro-
cytoma to glioblastoma took approximately 2–5  years 
[37]. Nevertheless, rapidly progressive cases of secondary 
glioblastoma have been reported [34]. Furthermore, as 
for brainstem gliomas, it has occasionally been reported 
that low-grade gliomas behaved as aggressively as high-
grade gliomas [38, 39]. Recent studies have revealed 
the histological heterogeneity of DIPG. Based on the 
autopsy results of the patients diagnosed with DIPG, It 
was reported that the primary and metastatic lesions dis-
played high and low histological grades, respectively [40, 
41]. Accordingly, DIPG was classified as primary lesions, 
contiguous lesions, and metastatic lesions according to 
the locations [41]. The different pathologic manifesta-
tions of the two samples from our case may be related 
to the differences of “central” and “marginal” areas of 
the lesion. This may again emphasize the importance of 
accurate sampling.
Immunohistochemical examination of our case dem-
onstrated a high positive rate of P53 (80%–90%), which 
is a frequently expressed marker of DIPG [42]. It was also 
reported that P53 mutation was even more frequently 
and increasingly expressed in secondary glioblastomas, 
which was in contrast with its rare expression in pri-
mary glioblastoma [34]. However, IDH1, a biomarker of 
secondary glioblastoma [43], showed low expression in 
our case. This may highlight the molecular differences 
between pediatric and adult secondary glioblastomas 
[44–46]. In children, low expression of IDH1 may be 
present in secondary glioblastomas. According to the 
literature, histological or imaging evidence of a progres-
sion from a less malignant astrocytoma can be used as 
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a diagnostic criterion of secondary glioblastomas [34]. 
Based on this knowledge and results of repeated MRI 
(MRS), in combination with initial PET–CT findings, we 
were inclined to diagnose our case as a rapidly progres-
sive secondary glioblastoma.
Multiple gadolinium-enhanced lesions are rarely seen 
in brainstem gliomas [47–49]. Multiple-lesion gliomas 
involve at least two enhanced lesions and account for 
2%–9% of all gliomas [50–52]. This rare entity is classi-
fied into two distinct types, multifocal and multicentric 
gliomas. Multifocal gliomas possess homology or dis-
semination of definite pathways. Multicentric gliomas are 
defined as anatomically isolated lesions and are usually 
distributed at different lobes or hemispheres of the brain 
[51]. Multiple lesions can be present at the diagnosis or 
at a progressive stage for both multicentric and multifo-
cal gliomas [53]. In our case, the right pontine lesion was 
developed at a later stage as compared with the other two 
lesions, and all lesions were located at the diffusely swell-
ing pons, indicating a diagnosis of multifocal glioblas-
toma rather than multicentric glioblastoma.
Diffuse pontine glioma is the most common type of 
brainstem tumor and carries the poorest prognosis in 
children [23]. Early surgical intervention to determine the 
diagnosis is recommended [54–56]. The standard treat-
ment of DIPG is external beam radiation therapy admin-
istered in fractions over approximately 6 weeks at a total 
dose of 60  Gy [54]. Diffuse intrinsic pontine glioma is 
almost invariably fatal with a mean patient overall sur-
vival of 9–12  months from the time of diagnosis [57]. 
Radiation therapy is the major treatment [58]. Adjuvant 
therapies, such as chemotherapy, targeted therapy, differ-
entiation agents, and radiation sensitizers, have been stud-
ied. Although some of these therapies showed a beneficial 
impact on patient outcomes [25, 58], further research is 
required.
Conclusion
In summary, we presented a rare case of progressive, exo-
phytic, multifocal pontine glioblastoma in a 5-year-old 
girl. A preoperative differential diagnosis was difficult 
because of the atypical neurological imaging features and 
frequent fever and cough symptoms. The clinical evi-
dence supported a secondary glioblastoma. Regretfully, 
an early histopathologic diagnosis was not achieved.
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